Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Certican

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

everolimus

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up.
BACKGROUND Everolimus is a proliferation signal-inhibitor recently introduced in heart transplant recipients. To date, little is… Expand
Is this relevant?
2007
2007
Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients.
BACKGROUND/METHODS This observational study reports on immunosuppression with cyclosporine (CsA) in 38 de novo heart transplant… Expand
Is this relevant?
2007
2007
Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference.
Everolimus (Certican; Novartis Pharma AG, Basel, Switzerland) represents the latest generation of proliferation signal inhibitors… Expand
Is this relevant?
Highly Cited
2007
Highly Cited
2007
12‐month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients
The proliferation signal inhibitor everolimus (Certican), has demonstrated efficacy with full‐dose cyclosporine (CsA) (Neoral… Expand
Is this relevant?
Review
2005
Review
2005
Concentration-Controlled Everolimus (Certican): Combination with Reduced Dose Calcineurin Inhibitors
The calcineurin inhibitors (CNIs) have been the cornerstone of immunosuppressive therapy in recent years, though their… Expand
Is this relevant?
Review
2005
Review
2005
Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure.
The proliferation signal inhibitor everolimus is efficacious for reducing the incidence of acute rejection and cardiac allograft… Expand
Is this relevant?
2005
2005
Clinical Experience with Everolimus (Certican): Optimizing Dose and Tolerability
Background. Everolimus (Certican), a novel proliferation signal inhibitor, allows calcineurin inhibitor dose reduction in… Expand
Is this relevant?
2005
2005
Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna.
  • A. Zuckermann
  • The Journal of heart and lung transplantation…
  • 2005
    • Corpus ID: 20672719
Innovations in immunosuppressant therapy often transfer from renal transplantation to heart transplantation. Accordingly, there… Expand
Is this relevant?
2005
2005
Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin.
Immunosuppressant agents have greatly increased graft and overall survival in heart transplant patients, but some of these agents… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Everolimus (Certican) 12-Month Safety and Efficacy Versus Mycophenolate Mofetil in de Novo Renal Transplant Recipients
Background. Everolimus is a proliferation inhibitor designed to target chronic rejection, including prevention of acute rejection… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE